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Early prediction of encephalopathy in hospitalized patients with
severe acute liver disease: The narrow window of opportunity
for transplant-free survivalq
Jacques Bernuau*, Francois Durand
APHP, Hoˆpital Beaujon, Poˆle des Maladies de l’Appareil Digestif, He´patologie, 100 Boulevard du Ge´ne´ral Leclerc, 92118 Clichy Cedex, FranceSee Article, pages 1021–1029Transplant-free survival, clearly the most suitable
outcome for any patient hospitalized (inpatient) with a
life-threatening acute liver disease (ALD), is unfortu-
nately uncommon among inpatients with acute liver
failure (ALF) not due to poisoning (paracetamol, mush-
room poisoning) (non-P) (non-P ALF). Despite some
recent improvements, transplant-free survival rates of
these patients, who were often in a good condition
before the onset of the causal ALD, remain low: 21%
[1] to 39% [2] in those with grade 3–4 hepatic encepha-
lopathy (HE), and 28% [3] to 67% [2] in those with grade
1–2 HE at admission to the liver unit. Even when IV N-
acetylcysteine (NAC) is given to patients with ALF not
due to paracetamol with grade 1–2 HE the survival rate
increases signiﬁcantly, but not above 52% [4]. In fact,
the transplant-free survival rate remains above 80% only
when, at admission to the liver unit, inpatients with non-
P ALD present with severe coagulopathy but without
HE [5], a condition often referred to as “severe ALD”,
“severe acute hepatitis” or “severe hepatic insuﬃciency”
[6]. The survival rate of such patients still remains >80%0168-8278/$36.00  2009 European Association for the Study of the Liver.
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prothrombin; LT, liver transplantation.even when patients at very low lethal risk such as those
with acute hepatitis type A, are not considered [5].
These ﬁve previous studies [1–5] indicate that preser-
vation of transplant-free survival of inpatients with
non-P ALD is closely related to the ability to recognize
early, during an often narrow window of opportunity
[7], those at increased risk of short-term development
of HE. As in Elinav’s study [5], it is therefore logical to
raise the question: “How to predict the short-term occur-
rence of HE in patients with ALD early enough in the
course of the disease?”. Among the three previously pub-
lished studies attempting to answer this question [5,8,9],
the only prospective one was restricted to patients with
paracetamol overdose [8]. In this issue of the Journal,
Takikawa and coworkers, from Japan, report the results
of a 13-year prospective study that aimed to predict HE
for inpatients with non-P ALD [10]: (a) HE was pre-
dicted with 100% sensitivity and 69% speciﬁcity, or
62% sensitivity and 93% speciﬁcity, when taking cut-oﬀ
values of HE-developing probability >20% or >50%,
respectively; (b) the HE-predictive model included four
of the ﬁve variables used in the King’s College criteria
(KCC) established to determine short-term fatality rate
>80% in British patients with non-P ALF [11], namely
patient’s age, the cause of ALD, serum total bilirubin
and prothrombin (PT) ratio (% of control); (c) ﬁnally,
HE was predicted from 1 to 25 days prior to its onset
and half the inpatients with HE were admitted to the
liver unit more than 5 days before its onset.
Several features support the credibility of the model
developed by Takikawa et al. First, important method-
ological requirements for this type of study [11] werePublished by Elsevier B.V. All rights reserved.
978 J. Bernuau, F. Durand / Journal of Hepatology 51 (2009) 977–980fulﬁlled. Three independent, consecutive groups of
symptomatic ALD inpatients, all without HE, were
evaluated: the ﬁrst group allowed to establish the crite-
ria (PT ratio 680% of control) for registration in the
two others, the second group gave rise to the develop-
ment of the HE-prediction model, and the third group
was used to validate this model. Second, the emergence
in the HE-prediction model of four of the ﬁve variables
used in the KCC [11] is the cornerstone of the model.
Since KCC are used worldwide as criteria for liver trans-
plantation (LT) in ALF patients, as initially proposed
[11], they are universally regarded as robust criteria of
life-threatening liver dysfunction [12] and it makes sense
that a set of four among their ﬁve variables was found
prospectively to predict HE for non-P ALD inpatients.
Third, the current study conﬁrms a previous one [13]
in which the authors found similar results, but with
lower sensitivity and speciﬁcity of the model than those
reported in this study [10].
The main value of Takikawa’s current study is the
demonstration that the diﬃcult task of predicting
short-term occurrence of HE for inpatients with severe
non-P ALD is feasible, even with an annual incidence
of two HE cases (validation group) [10]. The authors
acknowledge that their results require country-speciﬁc
studies in order to be validated outside Japan. We sup-
port this view and think that hepatologists now have
an ethical duty to perform such prospective protracted
studies: a population-based surveillance study yielded a
3.3 per million annual incidence of ALF not due to par-
acetamol in the United States in 2001–2004 [14] and, in
their validation group, Takikawa et al. reported a 6.5%
HE prevalence, 8/124 inpatients over 4 years. Although
seven of these eight inpatients died, future prospective
studies would be beneﬁcial because they would help both
to reduce the unacceptably high prevalence of patients
admitted to the liver unit with grade 3–4 HE, 27% [3]
to 81% [2], and to increase low transplant-free survival
rates [1–3]. Early detection of inpatients with HE-threa-
tened ALD and their early transfer to a liver unit, ideally
close to LT facilities, will not only enable to correct pos-
sible aggravating cofactors in some patients [15], but also
to try to protect the still undestroyed liver tissue with
drug(s) therapy delivered over a suﬃcient period of time.
Since early IV NAC infusion improved signiﬁcantly
transplant-free survival of non-acetaminophen ALF
patients admitted to liver unit with grade 1–2 HE [4], it
may be anticipated that IV NAC infusion will be at least
as eﬀective in patients without HE. Other drugs, some of
them risky in patients with altered liver function, may be
potentially liver- or life-saving if administered as early as
possible to severe non-P ALD inpatients without HE:
antiviral therapy in acute ﬂare-up of type B hepatitis
[16] (protocolized in Takikawa’s study), IV acyclovir in
patients with ALD due to necrotizing herpesviruses
[17,18], D-penicillamine in uncommon cases of rapidlyprogressing acute forms of Wilson’s disease [6] and hep-
arin-based anticoagulation in patients with acute forms
of Budd–Chiari syndrome [19]. Corticosteroids, recom-
mended in patients with severe acute auto-immune hep-
atitis without HE [20], may be associated with a high risk
of sepsis [21]. It could be argued that all these treatments
could be initiated and supervised in medical wards other
than liver units and the patients could be transferred to
these units only when further deterioration of liver func-
tion is observed. We disagree with this wait-and-see
strategy which, too often, ends with admission to the
liver unit of aggravated ALD inpatients with established
HE. Moreover, when the patient’s condition deteriorates
after a few days despite medical management in liver
unit, LT may be considered in parallel to the unfavour-
able course and will be more easily decided, as reported
in patients with Amanita phalloides poisoning [22].
Considering results when cut-oﬀ value of HE-devel-
oping probability is 50%, the HE-predicting model by
Takikawa et al. has intrinsic drawbacks despite 91%
accuracy. Half the patients in the validation group were
admitted to the liver unit less than 5 days before HE, an
interval sometimes too short to obtain the full eﬃcacy of
some drugs used to support the acutely injured liver.
Moreover, although maximal sensitivity should be priv-
ileged to reduce the rate of admissions to the liver unit
after the onset of HE [13], the sensitivity of the model
was only 62%. Several ways for improving sensitivity
are to be considered. Whereas the HE-model was based
on a single determination of the PT ratio (% of control),
its decrease over time might be demonstrated by serial
dosages (even several times a day) as reported for indi-
vidual coagulation factors [5]. Although the interval
between the onset of jaundice and HE exceeding 7 days
in patients with non-P ALF has a pejorative prognostic
value [11], it remains to be demonstrated whether time
duration of jaundice at evaluation, together with persis-
tently decreased PT ratio, might be associated with
increased risk of HE in patients with non-P ALD.
Finally, decreasing the cut-oﬀ value from 50% to 20%
increases the sensitivity up to 100%, but reduces speciﬁc-
ity to 69% (Fig. 4 in [10]). However, the use of the model
may be modulated according to the accepted risk of
overtransfer to liver units of some patients who will
recover without HE. The extra cost of such overtrans-
fers should be well compensated by the avoidance of
deaths or life-saving LTs in other patients.
Despite the above criticisms, several data contained in
Takikawa’s study should allow to improve the indications
for urgent transfer of non-P ALD inpatients to a liver
unit. Age >50 years and unfavourable etiologies (Fig. 2
in [10]) are are clearly related to an increased risk of
short-term occurrence of HE in the Japanese inpatients.
Initial PT ratio was <50% in 7/8 non-P ALD Japanese
inpatients who developed HE (Fig. 5 in [10]) and, thus,
could be set as a discriminatory level below which high
Table 1
Proposed criteria for immediate transfer to a liver unit with liver transplantation facilities of inpatients with non-poisoning acute liver disease (non-P
ALD) and coagulopathy, but without HE (organisation and duration of the transfer should be taken into account for the timing of the decision).
PT ratio (% of control) Additional characteristics of inpatients with non-P ALD
50–30 One of the following variables (1–8) is required for immediate transfer to a liver unit:
(1) Children (<15 years)a
(2) Adults >40 yearsa and unfavourable etiologyb
(3) Non-P ALD with fever >38 C or uncommon etiologyc
(4) Post-operative ALDd
(5) Pregnancy
(6) ALD superimposed on chronic liver diseasee (especially when the latter was previously stable and well
compensated)
(7) Comorbidity at special risk: diabetes mellitus, human immunodeﬁciency virus infection, previously cured cancer,
malaria, severe acute renal failure
(8) Hyperbilirubinemia >250 lmol/L [5,10]
<30 (1) Any non-P ALD patientf (especially patientsf of age >40 yearsa or unfavourable etiologyb)
a Age: KCC for LT (age <10 or >40) [11]; Takikawa’s criteria of increased HE risk (age >50) [10].
b Unfavourable etiology: KCC for LT [11]: drug-induced liver, undetermined etiology; Takikawa’s criteria of increased HE risk [10]: acute ﬂare-up
of hepatitis B virus chronic infection, auto-immune hepatitis, undetermined etiology.
c ALD due to necrotizing herpesviruses (fever); (even still unclearly characterized) Wilson’s disease, Budd–Chiari syndrome, post-aspirin Reye’s
syndrome.
d After non-hepatic surgery in patients not given anti-vitamin K therapy.
e The chronic liver disease may be previously diagnosed, or only suspected (“decompensated” cirrhosis is not included here).
f Except previously normal subjects with acute hepatitis type A, or C, or acute hepatic ischemia.
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the indications currently recommended at Hoˆpital Beau-
jon for referral of non-P ALD inpatients to a liver unit,
ideally with LT facilities (and not necessarily in a liver
intensive care unit). Criteria for such a referral should
be of lesser severity than those for LT. One of eight addi-
tional characteristics is required to transfer inpatients
with non-P ALD and initial PT ratio ranging between
50% and 30%, whereas any inpatient with non-P ALD
and initial PT ratio <30% (except previously normal
patients with low-risk ALD) should be transferred, to a
liver unit.
In conclusion, persisting to follow the usual recom-
mendation to refer non-P ALD inpatients to a liver unit
at the onset of HE will maintain a low rate of trans-
plant-free survival. On the contrary, it might prove ben-
eﬁcial to many of these patients to be transferred to a
liver unit earlier in the course of the causal disease, on
the basis of several of the features emerging from the
important prospective study in this issue by Takikawa
et al. and indicating a high risk of HE.
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